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CLINICAL AND POPULATION STUDIES
Human Y Chromosome Exerts Pleiotropic Effects 
on Susceptibility to Atherosclerosis
James M. Eales, Akhlaq A. Maan, Xiaoguang Xu, Tom Michoel, Pille Hallast, Chiara Batini, Daniel Zadik,  
Priscilla R. Prestes, Elsa Molina, Matthew Denniff, Juliane Schroeder, Johan L.M. Bjorkegren, John Thompson,  
Pasquale Maffia, Tomasz J. Guzik, Bernard Keavney, Mark A. Jobling, Nilesh J. Samani, Fadi J. Charchar, Maciej Tomaszewski
OBJECTIVE: The male-specific region of the Y chromosome (MSY) remains one of the most unexplored regions of the genome. 
We sought to examine how the genetic variants of the MSY influence male susceptibility to coronary artery disease (CAD) 
and atherosclerosis.
APPROACH AND RESULTS: Analysis of 129 133 men from UK Biobank revealed that only one of 7 common MSY haplogroups 
(haplogroup I1) was associated with CAD—carriers of haplogroup I1 had ≈11% increase in risk of CAD when compared with all 
other haplogroups combined (odds ratio, 1.11; 95% CI, 1.04–1.18; P=6.8×10−4). Targeted MSY sequencing uncovered 235 
variants exclusive to this haplogroup. The haplogroup I1–specific variants showed 2.45- and 1.56-fold respective enrichment 
for promoter and enhancer chromatin states, in cells/tissues relevant to atherosclerosis, when compared with other MSY 
variants. Gene set enrichment analysis in CAD-relevant tissues showed that haplogroup I1 was associated with changes 
in pathways responsible for early and late stages of atherosclerosis development including defence against pathogens, 
immunity, oxidative phosphorylation, mitochondrial respiration, lipids, coagulation, and extracellular matrix remodeling. UTY 
was the only Y chromosome gene whose blood expression was associated with haplogroup I1. Experimental reduction of 
UTY expression in macrophages led to changes in expression of 59 pathways (28 of which overlapped with those associated 
with haplogroup I1) and a significant reduction in the immune costimulatory signal.
CONCLUSIONS: Haplogroup I1 is enriched for regulatory chromatin variants in numerous cells of relevance to CAD and increases 
cardiovascular risk through proatherosclerotic reprogramming of the transcriptome, partly through UTY.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words:  coronary artery disease ◼ epigenomics ◼ gene expression ◼ humans ◼ risk factors
Transmitted as an indivisible portion of DNA from fathers to sons, the male-specific region of the Y chromosome (MSY) constitutes 95% of the entire 
length of the human Y chromosome.1 Since the diver-
gence of both sex chromosomes from a pair of auto-
somes 300 million years ago, the gene content of 
the MSY has been significantly reduced, and the Y is 
now one of the smallest chromosomes with the lowest 
gene content.2 However, recent studies revealed that 
mammalian evolution fixed at least a handful of ubiqui-
tously expressed genes on MSY because of their appar-
ent importance to male viability and survival.3
The MSY does not routinely recombine or exchange 
genetic material with any other elements of the genome.4,5 
Because of its haploid nature, the MSY has been rou-
tinely excluded from genome-wide association studies.4 
See accompanying editorial on page 2201
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As a result, there is a gap in knowledge on how the 
genetic variation within the human Y chromosome con-
tributes to male health and susceptibility to disease. Our 
previous analysis of MSY showed that one of its common 
European lineages, haplogroup I, was associated with 
increased risk of coronary artery disease (CAD) when 
compared with other haplogroups.5 This association was 
independent of conventional cardiovascular risk factors.5 
Our further transcriptome-wide analysis of human mac-
rophages revealed that a majority of autosomal gene sets 
showing differential expression between haplogroup I 
and other MSY lineages map to immune and inflamma-
tory pathways.5 Collectively, these data suggest that the 
MSY genetically regulates susceptibility to CAD, possibly 
through modulation of the immune response. This adds 
to an expanding body of evidence from experimental ani-
mal models and human studies suggesting that genetic 
variation within the Y chromosome plays an important 
role in male health.6
Here, through a phylogenetic analysis of 129 133 Y 
chromosomes, we uncover a new association between 
one of the MSY lineages (haplogroup I1) and CAD. 
Through DNA sequencing of the MSY combined with 
analysis of chromatin state across 21 epigenomes, we 
further demonstrate that this paternal lineage of the 
Y chromosome is enriched for genetic variants with a 
functional effect on gene expression in cells and tis-
sues of relevance to atherosclerosis. Our transcrip-
tome-wide analyses in tissues of relevance to CAD 
show that haplogroup I1 carriers exhibit changes in 
gene expression in numerous pathways known for 
their role in atherosclerosis—immunity, response to viral 
infection, energy and lipid metabolism, coagulation, and 
hemostasis, as well as extracellular remodeling. Finally, 
our studies implicate a single MSY gene whose experi-
mentally reduced expression in human macrophages 
leads to changes in expression of genes and pathways 
partly replicating those under the genetic control of 
haplogroup I1.
MATERIALS AND METHODS
Association Between Y Chromosome 
Haplogroups and CAD
UK Biobank—Y Chromosome Genotyping
UK Biobank utilized 2 genotyping arrays: ≈50 000 individuals 
were genotyped on UK BiLEVE array, and the remaining indi-
viduals on the UK Biobank Axiom array.7 These 2 arrays harbor 
813 and 1041 single-nucleotide variants of the Y chromosome, 
respectively. At the time of our analyses, genetic data were avail-
able for 223 513 male individuals. A series of stringent quality 
control (QC) procedures were undertaken at both the geno-
type and sample level (Figures I and II in the online-only Data 
Supplement). Four metrics were used as a QC check for the Y 
chromosome variants on each array (Figure I in the online-only 
Data Supplement). These included (1) applying UK Biobank inter-
nal variant QC, (2) overlap with International Society of Genetic 
Genealogy (ISOGG; www.isogg.org) variants, (3) exclusion of vari-
ants with low call rate, and (4) exclusion of monomorphic variants. 
A total of 162 Y chromosome variants survived the QC analysis 
and were used for the purpose of haplogroup analysis. A separate 
QC pipeline was used to exclude samples of insufficient quality 
before the association analysis (Figure II in the online-only Data 
Supplement). These included assessment of genotype missing-
ness rate, heterozygosity, familial relatedness, genetic sex, and 
genetic ancestry. The number of samples excluded at each stage 
of the QC process together with the number of surviving samples 
are shown in Figure II in the online-only Data Supplement. Of 
169 648 individuals surviving the QC filters, 168 686 had match-
ing fully informative Y chromosome haplogroup information.
UK Biobank—Phylogenetic Analysis
Using genotype call data for Y chromosome variants that had 
passed QC, PED and MAP files were generated as input to the 
yHaplo8 software—custom-designed software for Y chromosome 
Nonstandard Abbreviations and Acronyms
CAD coronary artery disease
GSEA gene set enrichment methodology
GTEx Genotype-Tissue Expression
ISOGG  International Society of Genetic Genealogy
MSY  male-specific region of the Y chromosome
QC quality control
SNP single-nucleotide polymorphism
STAGE  Stockholm Atherosclerosis Gene Expression
Tss transcription start site
UTY  ubiquitously transcribed tetratricopeptide 
repeat containing, Y linked
Highlights
• Y chromosome haplogroup I1 is associated with an 
increased risk of coronary artery disease.
• Genetic variants specific to haplogroup I1 show an 
enrichment in overlap with transcription start site 
and enhancer chromatin states in epigenomes from 
cells and tissues relevant to coronary artery disease.
• We have identified gene expression pathways 
involved in both early and late stages of atheroscle-
rosis, which are perturbed in men who inherited hap-
logroup I1 from their fathers.
• The expression of one of Y chromosome genes 
(UTY) is reduced in blood samples from men with 
haplogroup I1 when compared with those with other 
haplogroups.
• Experimental reduction in expression of UTY leads 
to perturbation of pathways of gene expression 
related to atherosclerosis and a significant reduction 
in abundance of the costimulatory proteins CD80 
and CD83 in induced macrophages.
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haplogroup assignment. In brief, yHaplo8 uses a reference phyloge-
netic tree structure with haplogroup-defining single-nucleotide poly-
morphisms (SNPs) that is regularly updated to reflect refinements 
by ISOGG. For each individual, the algorithm traverses through the 
branches of the phylogenetic tree according to SNP calls, starting 
at the root and stopping when the most terminal branch possible is 
reached.8 A total of 85 MSY haplogroups were identified by yHaplo 
(see Figure 1A; Table I in the online-only Data Supplement). Of 
those, 7 groupings (E, G, I1, I2, J, R1a, and R1b) within the top level 
of the MSY phylogenetic tree were present in >1% of men.
UK Biobank—CAD Phenotyping
CAD was defined using hard end point criteria derived from self-
assessment, hospital episode statistics, and death registry data in 
the UK Biobank cohort. Patients with CAD (cases) were defined 
as (1) men with either self-reported or hospital episode statistics-
documented history of myocardial infarction or coronary revascu-
larization procedures, including percutaneous coronary intervention 
or coronary artery bypass graft and (2) men whose death had been 
attributed to CAD in death registry data. CAD-free controls were 
defined as men with no history of angina, unstable angina, myocar-
dial infarction, coronary revascularization, death due to CAD or tak-
ing common CAD medications (aspirin, glyceryl trinitrate, isosorbide 
mononitrate/dinitrate, and nicorandil) across self-reported, hospital 
episode statistics, and death registry records. A total of 11 234 men 
with CAD and 117 899 CAD-free male controls were identified 
using these criteria (as illustrated in detail in a diagnostic decision 
tree developed for the purpose of this project [Figure III in the online-
only Data Supplement]) and had full information required for adjust-
ment for cofounders (Table II in the online-only Data Supplement).
UK Biobank—Genetic Association Analyses
For the purpose of our genetic association analysis, we selected 
all common (>1%) haplogroups identified through our phylogenetic 
analysis (E, G, I1, I2, J, R1a, and R1b). The association analysis was 
conducted by multiple logistic regression with CAD as the depen-
dent variable and binarized haplogroup status of the Y chromo-
some (ie, E versus others), age, body mass index, genotyping array, 
hypertension, physical activity level, household income, smoking, 
completion of further education, employment status, alcohol intake 
frequency, paternal and maternal history of heart disease, and 5 
genetic principal components extracted from autosomal genotypes 
were independent variables (Tables II through IX in the online-only 
Data Supplement). Similar to other genetic studies on individuals of 
white British ancestry,9 we adopted the first 5 principal components 
in our regression models to account for effects of hidden population 
structure. These components are the first 5 of 40 principal compo-
nents generated in UK Biobank using 147 604 autosomal single-
nucleotide variants in 407 219 biologically unrelated individuals of 
different ethnicities.7 Given 7 multivariate logistic regression models 
constructed in our genetic association analysis, the Bonferroni cor-
rection for multiple testing was applied at P=0.0071 (0.05/7). For 
the purpose of validation, we conducted an additional analysis of 
association between haplogroup I1 and CAD using a different set 
of diagnostic criteria of CAD, as applied to UK Biobank by Klarin 
et al.10 This analysis of association was conducted using the same 
statistical model and the same set of covariates as specified earlier.
Next-Generation DNA Sequencing of 
Haplogroup I1
We combined data from 3 separate DNA-sequencing experi-
ments to obtain the most extensive list of genetic variants 
associated with haplogroup I1: (1) de novo targeted sequenc-
ing of MSY regions with the strongest potential of biological 
functionality, (2) previously conducted targeted high-coverage 
sequencing of 3.7 Mb of MSY DNA,11,12 (3) low-coverage whole 
genome sequencing in the 1000 Genomes Project.13,14
De Novo Targeted MSY DNA Sequencing
Individuals
Forty-eight white British individuals were selected from 
those recruited previously.15 Individuals were selected on 
the basis of genotyping data for key UK haplogroup-defin-
ing markers including M170 for haplogroup I and M269 for 
R1b1b2 haplogroups. Of the selected individuals, 15 men 
were confirmed as carriers of haplogroup I1 by genotype 
comparison of 5 different haplogroup I1 defining single-
nucleotide variants from the ISOGG reference set.
Sequencing Targets
Genes. Using Ensembl (release 75) as a reference, 
we designed amplicons to cover all exons, introns, and 
3′- and 5′-untranslated regions (together with 100-bp 
adjacent downstream and upstream sequences) of all 
known protein-coding and noncoding genes on the MSY 
(coding status defined by Ensembl attribute gene_bio-
type). Amplicons were screened by the Agilent HaloPlex 
SureDesign service to remove amplicons covering highly 
repetitive DNA (using balanced amplicon selection; Table 
X in the online-only Data Supplement).
Transcription Factor–Binding Site Targets. Through 
an analysis of Encyclopedia of DNA Elements (ENCODE) 
chromatin immunoprecipitation sequencing (ChIP-seq) 
data, we identified 522 putative transcription factor–
binding sites. Putative transcription factor–binding sites 
were extracted from ENCODE ChIP-seq peak calling 
outputs (peakSeq) for all available tissues and cell types 
and across all transcription factors available. BigBed files 
generated by peakSeq were first converted to bed and 
then filtered for peaks on chrY; these were then sorted 
by chromosomal position and merged using bedtools 
resulting in 522 putative sites that were then extended 
to a minimum of 500 bp. Amplicons covering the sites 
were created and screened for repetitiveness by Agilent 
SureDesign (using maximum-specificity amplicon selec-
tion; Table X in the online-only Data Supplement).
Novel Transcribed Regions. Analysis of RNA-sequencing 
data from monocyte and macrophage cell isolates (sam-
ples prepared as in the study by Schunkert et al16) identi-
fied 8 regions of the Y chromosome that show signs of 
active transcription but are not covered by gene annota-
tions in Ensembl. Reads were aligned to the Ensembl 
GRCh37 genome (using the transcriptome reference gtf, 
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Ensembl, version 75) using TopHat. Intergenic regions 
containing >10 gapped reads and with mapping quality 
>20 were included as targets for sequencing.
Haplogrouping SNPs. We also targeted 2972 Y chromo-
some haplogrouping SNPs identified from 3 sources: the 
ISOGG SNP index (https://isogg.org/tree/ISOGG_YDNA_
SNP_Index.html), the variant list from Wei et al,17 and the 
Illumina HumanExome genotyping array (HumanExome-
12-v1-2-B). Haplogrouping SNPs were sorted by chromo-
somal position and merged (to remove duplicate SNPs).
The full set of 3648 MSY target regions gained an 
amplicon coverage of 78%, covering 3665 kb of MSY 
sequence (Table X in the online-only Data Supplement). 
The summary characteristics for the sequenced targets 
are shown in Table X in the online-only Data Supplement.
DNA Sequencing
The targeted regions were selected and enriched for 
using an Agilent Haloplex kit (with adapter ligation for 
Illumina sequencers). The enrichment process was per-
formed at the Oxford Genomics Centre at the Wellcome 
Trust Centre for Human Genetics. Input to the Haloplex 
process was 225 ng of genomic DNA (extracted from 
peripheral blood). Sequencing libraries with Illumina 
adapters were constructed as part of the Haloplex pro-
tocol. All libraries were simultaneously sequenced across 
2 lanes of a high-output run on an Illumina HiSeq2000 
using 100-bp paired-end reads.
Read QC and Mapping
Raw reads first underwent QC checks including man-
ual inspection of per sequence, per tile, and per base 
read quality distributions, as well as sequencing adapter 
content and per base sequence content by FastQC 
(https://www.bioinformatics.babraham.ac.uk/projects/
fastqc/) run with the --nogroup argument. Raw reads 
were trimmed using trimmomatic18 in paired-end mode 
with the input arguments SLIDINGWINDOW:5:20, MIN-
LEN:35, and ILLUMINACLIP:adapters.fa:3:15:3:1:true. 
Reads were mapped to the GRCh37 human genome 
reference using Bowtie2 with default arguments.
Variant Calling
A total of 5.12 Gbp of MSY-mapped read data from 15 
men with haplogroup I1 underwent variant calling using 
the GATK HaplotypeCaller (GATK v419). HaplotypeCaller 
was set to a ploidy of one and was limited to 3 alternative 
alleles per variant site. We applied a set of variant filtering 
criteria using the GATK tool (v4), VariantFiltration, all filter 
specific criteria are outlined in Table XI in the online-only 
Data Supplement. To test the stability of our variant calling 
process, we screened for false-positive and false-negative 
variants using a DNA sample from the 1000 Genomes 
Project, the same individual had undergone Complete 
Genomics whole genome sequencing, a high-quality cus-
tom genome sequencing process that produces variant 
calls with a high level of reliability. A comparison of our 
variants calls with the Complete Genomics set did not 
identify a single instance of false-positive or false-nega-
tive variant calls. A total of 1463 unique variants including 
1112 SNPs and 351 insertion-deletions were called and 
retained for further analysis.
High-Coverage Sequencing of MSY
Individuals
A total of 448 men representing a worldwide spectrum 
of MSY phylogeny underwent high-coverage (≈51×) 
sequencing of 3.7 Mb of MSY DNA.11,12 From this data-
set, we selected 4 men of European ancestry who were 
identified as carriers of haplogroup I1 based on hap-
logroups from Hallast et al.12
Library Preparation, Sequencing, and QC
Full experimental details are available elsewhere.11,12 In 
brief, 3 to 5 µg of genomic DNA extracted from peripheral 
blood was used for library preparation and SureSelect (Agi-
lent Technologies) target enrichment. The samples were 
sequenced with paired-end 100-bp reads on an Illumina 
HiSeq2000. All reads were mapped to the GRCh37 human 
genome reference, subjected to stringent quality filters and 
comparison to complete genomics reference genotypes for 
a set of 1000 Genomes reference DNA samples.
Variant Calling
From the whole dataset, we obtained 1.59 Gbp of aligned 
and filtered reads from 4 men with haplogroup I1. Vari-
ant calling was conducted using identical methods to 
those above. A total of 1202 unique variants including 
1037 SNPs and 165 insertion-deletions were called and 
retained for further analysis.
MSY Variants From Phase 3 of the 1000 Genomes Project
Individuals
A total of 31 individuals with haplogroup I1 were selected 
from the 1000 Genomes Project (phase 3 release)13,14 
for the purpose of this analysis. We selected these indi-
viduals based on haplogroup inferences made as part of 
the 1000 Genomes Project phase 314.
Variant Calls
Variants for each haplogroup I1 individual were selected 
from the phase 3 variant call format files for the Y 
chromosome (ftp://ftp.1000genomes.ebi.ac.uk/vol1/
ftp/release/20130502/ALL.chrY.phase3_integrated_
v2a.20130502.genotypes.vcf.gz). We excluded copy 
number variants from the analysis (ie, an alternative allele 
of “<CN0>” or “<CN1>”). We checked the specificity of 
our haplogroup I1–specific variants by comparing all 
variants shared by all our haplogroup I1 samples against 
those found in all other 1000 Genomes Project samples; 
any overlapping variants were excluded.
Combination of MSY Variants From 3 Experiments
We combined all haplogroup I1 MSY variant calls from the 3 
experiments into a single master variant call set by merging 
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them on GRCh37 start and end position, as well as reference 
and alternative alleles using R. We also recorded the presence 
(or absence) of every variant in each of the 3 datasets.
Functional Analysis of Haplogroup I1–Specific 
Variants in Cells and Tissues of Relevance to 
Atherosclerosis and CAD
Summarization of Roadmap Epigenomics 15-State 
Chromatin Segmentation
The Roadmap Epigenomics 15-state chromatin segmentation 
data20 labels human genome with one of 15 possible chromatin 
states20 across 127 epigenomes derived from human tissues 
and cell lines. Of those, we selected 21 epigenomes (Table XII 
in the online-only Data Supplement) based on their known rel-
evance to atherosclerosis or CAD. We grouped the 15 chro-
matin states into 4 states using a combination of histone mark 
specificity (Table XIII in the online-only Data Supplement) and 
the 15-state clustering reported by Roadmap Epigenomics in 
their extended data.20 In brief, states 1 to 3 were combined 
into transcription start site (“Tss”; based on H3K4me4), states 
4 and 5 into “transcribed” (based on H3K36me3), and states 
6 and 7 into “enhancer” (H3K4me1); the remainder were com-
bined into a “silent/other” state.
Mapping Genetic Variants to Chromatin Regions With 
Functional Potential
We computed the overlapping chromatin state for each iden-
tified haplogroup I1 variant in each of the 21 epigenomes 
using GRCh37 start and end positions for each variant, 
allowing for a variant to overlap with >1 state (within a single 
epigenome).
Summarized Active Chromatin State Enrichment Analysis
The chromatin states for the identified 235 haplogroup I1 variants 
were compared with all common (those with at least 1% minor 
allele frequency) nonhaplogroup I1 MSY variants from European 
1000 Genomes Project phase 3 individuals. Further sensitivity 
analyses were restricted to 216 haplogroup I1 variants present 
in the 1000 Genomes Project (phase 3 release) and compared 
with the same MSY reference (all European MSY variants with at 
least 1% minor allele frequency). The P for enrichment in active 
chromatin states in haplogroup I1 variants in both the athero-
sclerosis/CAD-relevant set and for other epigenomes was cal-
culated by 1 million random permutation of the haplogroup I1 
variants; for each permutation, the fold enrichment is calculated 
and compared with the fold change for nonpermuted variants. 
The final P was calculated by counting the number of permu-
tations where the nonpermuted enrichment value is exceeded 
divided by the number of permutations performed.
To compare the enrichment in active chromatin states for 
haplogroup I1 variants between atherosclerosis/CAD-relevant 
and other epigenomes, we generated 1 million random per-
mutations of epigenomes not included in the atherosclerosis/
CAD-relevant set and calculated the fold enrichment between 
I1 and common MSY SNPs for each state in each permuta-
tion. A P for each chromatin state was calculated by counting 
the number of permuted fold-enrichment values that exceeded 
the fold enrichment in CAD-relevant epigenomes divided by the 
number of permutations performed.
For the Genotype-Tissue Expression (GTEx) project eSNP 
comparison, we first identified 2 Roadmap epigenomes that 
had a pair in the GTEx V6 eQTL analysis output (aorta and 
left ventricle, https://www.gtexportal.org/home/datasets). We 
selected the GTEx results for each tissue to only include the 
most statistically significant eSNPs (identified by is_chosen_
snp=1). This identified 4417 SNPs for left ventricle and 6220 
for aorta. As a comparator to the GTEx eSNPs, we used com-
mon SNPs from the dbSNP common_all data set (build 150); 
this includes SNPs with minor allele frequency >1% in at least 
one of 26 major human populations. We removed all known 
eSNPs (identified by GTEx v6) from dbSNP before any com-
parisons were made, leaving 37 436 593 SNPs for the analysis.
Pathway Analysis of Gene Expression Data 
From GTEx
MSY Genotypes and Haplogrouping of GTEx Men
Called genotypes (in variant call format) for each male GTEx 
individual genotyped by Illumina DNA sequencing were down-
loaded from dbGaP (database of genotypes and phenotypes). 
We excluded individuals with <80% call rate of Y chromosome 
markers; this yielded 178 male individuals suitable for phyloge-
netic analysis. Genotypes for M170 (a marker for haplogroup 
I) and M253 (a marker for haplogroup I1) were extracted and 
compared with ISOGG data to identify haplogroup informative 
genotypes to classify each individual as I1 (having genotypes 
M170=C and M253=T) or other (having genotypes M253=C).
Principal Components
Three principal components were derived from autosomal 
genotype data generated by the GTEx project using genotypes 
from the Illumina Omni 5M array and compared between car-
riers of haplogroup I1 and men with other lineages of the Y 
chromosome using a Kolmogorov-Smirnov test.
Differential Gene Expression Analysis
The GTEx read count table (release V6p) was downloaded 
from the GTEx portal. Read count data for every tissue of each 
haplogrouped sample were extracted. As recommended by 
GTEx, samples with unreliable transcriptome information were 
removed (subject phenotype field SMTORMVE=FLAGGED), 
leaving 173 male individuals with informative read count data. 
We tested each of 8 different tissues of relevance to CAD 
(Table XIV in the online-only Data Supplement)—for differential 
expression between men with haplogroup I1 versus men who 
are carriers of other haplogroups. Differential expression analy-
sis was conducted by DESeq221,22 with GTEx read counts as an 
input. The analysis was adjusted for age, body mass index, sam-
ple ischemic time, sample sequencing center, and a variable 
number of surrogate variables. The number of surrogate vari-
ables calculated per tissue was 10% of the number of samples 
tested. Surrogate variables were calculated by SVASeq23 on the 
middle 80% of expressed genes in each tissue. The top and 
bottom 10% were excluded to reduce the impact of highly and 
weakly expressed genes,23 which are more likely to generate 
artifactual read count values. Outlier read count observations 
(per gene) were identified and replaced by DESeq221,22 using 
Cook distances and the trimmed mean of read counts per 
gene. In all differential expression analyses, MSY haplogroup 
was binarized into “I1” and “other” values, with other set as the 
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reference level. Thus, all differential expression and pathway 
analysis outputs show deviation of haplogroup I1 expression 
from other haplogroups, with a positive coefficient (effect size) 
indicative of higher expression in men with haplogroup I1 than 
among others. Using the full output from DESeq2, we then 
extracted the T statistic for every tested gene, and these were 
provided as input to our pathway analysis.
Pathway Analysis
Our pathway analysis followed the gene set enrichment analy-
sis (GSEA) methodology.24 This approach to transcriptome 
analysis can detect subtle differences in expression of pre-
defined biologically coordinated gene sets from the Molecular 
Signatures DataBase embedded in the KEGG, BIOCARTA, 
and REACTOME pathway repositories. Our analysis was 
conducted on tissues of relevance to atherosclerosis/CAD 
between men with haplogroup I1 and those from other hap-
logroups (as reported above). The pathway analysis testing 
process was performed by the R package fgsea on the canoni-
cal pathways gene set from Molecular Signatures DataBase 
(v5.1 c2.cp.v5.1.symbols.gmt) with a million permutations on 10 
processors. Input was the distinct set of HGNC (HUGO gene 
nomenclature committee) gene symbols with their associated 
T statistics from the DESeq2 differential expression test-
ing process. Significant pathways were identified by having a 
Benjamini-Hochberg (false discovery rate)–adjusted P<0.05. A 
positive normalized enrichment score corresponds to increased 
expression of leading edge genes within a given pathway in 
carriers of haplogroup I1. Immunity subthemes, themes, and 
immune-relevant genes were determined by 2 independent 
experts in immunology.
Pathway Analysis of Gene Expression Data 
From the STAGE Study
STAGE Cohort Characteristics
The STAGE study (Stockholm Atherosclerosis Gene Expression) 
collected a set of 612 tissue samples from Swedish individu-
als.25 Gene expression and genotype data have been derived for 
each sample using the custom Affymetrix HuRSTA-2a520709 
and the Affymetrix GenomeWideSNP_6 arrays, respectively. 
For the purpose of this analysis, we selected atherosclerotic 
artery wall (AAW), subcutaneous fat (SF), visceral fat (VF), 
whole blood (WB) gene expression profiles from a total of 
92 men with available genotyping information (Table XV in 
the online-only Data Supplement). We included STAGE men 
in this project (1) to establish an independent replication for 
the findings from GTEx (2) to capture the potential differences 
between the compared haplogroups in pathways that may be 
quiescent in nondiseased tissues.
MSY Genotypes and Haplogrouping of STAGE Men
From the STAGE genotypes we extracted biallelic genotype 
calls for the 9 different haplogroup I1–specific markers rec-
ommended by the ISOGG database. Men whose alleles were 
consistent with the haplogroup I1–indicative allele across 
all markers were classified as carriers of haplogroup I1. We 
observed that the frequency of haplogroup I1 in STAGE is much 
higher (≈35%; Table XV in the online-only Data Supplement) 
than in GTEx (Table XIV in the online-only Data Supplement); 
this is in line with previously published estimates of prevalence 
of haplogroup I1 in Swedish population.25
Principal Components
We calculated the first 3 genetic principal components using 
the methods of the GTEx consortium26 on genotype data from 
the Affymetrix GenomeWideSNP_6 array. Principal compo-
nent values were compared between carriers of haplogroup 
I1 and men with other lineages of the Y chromosome using a 
Kolmogorov-Smirnov test.
Differential Gene Expression Analysis
STAGE gene expression data were background corrected and 
normalized using the Affymetrix GeneChip command console. 
Normalized probe intensities were examined for differential 
expression between I1 and other MSY haplogroups using linear 
regression adjusting for age and body mass index, with other 
set as the reference level. In consistency with the differential 
expression analysis conducted in GTEx, we extracted the gene 
symbols and T statistics as input to the pathway analysis.
Pathway Analysis
The pathway analysis for each STAGE tissue was performed 
in the same way as in the GTEx analysis. Immunity subthemes, 
themes, and immunity-relevant genes were determined by 2 
independent experts in immunology.
Sensitivity Analysis
A further differential gene expression analysis was conducted 
with additional adjustment for clinically relevant parameters 
including total cholesterol, HDL (high-density lipoprotein) 
cholesterol, hypertension, and treatment with lipid-lowering 
medication available in STAGE. In consistency with the primary 
analysis, gene symbols and T statistics from the differential 
gene expression analysis were used as input to the pathway 
analysis. All significant pathways from the primary analysis 
were retested by GSEA and the statistics compared between 
primary and the secondary sensitivity analysis (Table XVI in 
the online-only Data Supplement). All significant results from 
the primary analysis produced the same direction of pathway 
association (identical sign of the normalized enrichment score), 
388 of 389 results replicated at a nominal P of 0.05 and 386 
results (of 389) replicated at false discovery rate of 5%.
Experimental Reduction of UTY Gene 
Expression in Human Macrophages
Generation and Isolation of Macrophages
Peripheral blood mononuclear cells were isolated from a 
healthy male donor’s whole blood sample obtained from the 
Australian Red Cross, West Melbourne. Monocytes were con-
verted to macrophages using a recombinant human macro-
phage colony-stimulating factor–based technique reported in 
detail previously.5
UTY Knockdown by Antisense Oligonucleotides
We used advanced antisense oligonucleotides Locked Nucleic 
Acid longRNA GapmeRs—a class of high-affinity RNA ana-
logues that exhibit high thermal stability when hybridized to a 
cDNA or RNA strand—to reduce expression of UTY (ubiq-
uitously transcribed tetratricopeptide repeat containing, Y 
linked). Antisense Locked Nucleic Acid longRNA GapmeRs 
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were designed and synthesized by Exiqon. The transfection 
of the following GapmeRs, UTY_GapmeR (product sequence 
5′-3′: AATGGAGTGTCTGTGC), and negative control A (prod-
uct sequence 5′-3′: AACACGTCTATACGC) were performed 
using Lipofectamine 2000 (Thermo Fisher Scientific) following 
Exiqon manufacturer’s recommendations. Cells were seeded 
into 6-well plates at a density of ≈2×105/mL and cultured in 
DMEM supplemented with 10% HI-FBS, penicillin (100 U/mL), 
and streptomycin (100 µg/mL) until cells reached ≈70% conflu-
ence. Subsequently, cells were transfected with 10 nmol/L of 
antisense oligonucleotides in Lipofectamine 2000 reagent.
RNA Extraction and RNA Analyses
Forty-eight hours post-transfection, total RNA was extracted 
using the TRIzol reagent followed by a RNA cleanup step using 
miRNeasy kit (Qiagen). The knockdown was confirmed by real-
time quantitative polymerase chain reaction. The latter was 
performed using SYBR Green (Bioline) according to the manu-
facturer’s instructions. In brief, 20 ng (2 µL) of cDNA was added 
to 2.5 µL of SYBR Green qPCR reaction mix (Bioline) together 
with 200 nmol/L of each of the forward and reverse primer 
(Integrated DNA Technologies) and 0.3 µL of nuclease-free 
water in a final volume of 5 µL. We used the following UTY primers 
(forward primer, 5′-TCTACAGAATGGTTCTGATAACTGGAA-3′; 
reverse primer, 5′-GGTGTCAAACACAACGAATAAACTTG-3′) 
and the following primers for the control gene (GAPDH; for-
ward primer, 5′-CTCTGCTCCTCCTGTTCGAC-3; reverse 
primer, 5′-GCGCCCAATACGACCAAATC-3′). Amplification 
and detection were conducted under the following conditions: 
10 minutes at 95°C, 45 cycles of 15 s at 95°C and 1 minute 
at 60°C on Applied Biosystems ViiA 7 Real-Time PCR system 
(Life Technologies).
For the purpose of RNA sequencing, the libraries were con-
structed using 3 g of input macrophage RNA using the Illumina 
TruSeq RNA protocol with poly-A selection. Libraries were 
sequenced using 100-bp reads (on an Illumina HiSeq 2000) 
producing an average of 26.3 million reads and 2.63 Gb per 
sample. All generated raw reads were stored in FASTQ format. 
The base call and read quality were evaluated using FastQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
The input library complexity was assessed using RNA-SeQC.27 
cDNA, sequencing libraries, and raw RNA-sequencing data were 
generated at the Australian Genome Research Facility.
Differential Gene Expression Analysis and Pathway 
Analyses
Gene expression was quantified in all samples using Kallisto28 
and a transcriptome index built from Ensembl GRCh38 release 
83 with bias correction enabled, and 100 bootstrap quantifica-
tions were performed. Read counts were examined for differen-
tial expression between knockdown and control (with control as 
reference level) samples in the Sleuth R package29 using all 
100 bootstrap replicates and default parameters. Differentially 
expressed genes were identified by a Wald test29 at the signifi-
cance threshold of false discovery rate <0.05. Similar to stud-
ies in GTEx and STAGE, we extracted T statistics for all genes 
tested as an input to further GSEA-based pathway analysis. All 
GSEA analyses were performed in agreement with the prin-
ciples highlighted earlier.
All in vitro experiments were performed in triplicate across 2 
experimental conditions UTY knockdown and control.
Experimental Reduction of UTY Gene 
Expression in THP-1 Cells
Cell Culture and Transfection
THP-1 cells were seeded into 24-well plates at 5×105 cells in 
complete RPMI (10% fetal calf serum, 1% penicillin/strepto-
mycin, and 1% L-glutamine) and differentiated to macrophages 
with the addition of phorbol 12-myristate 13-acetate (10 ng/
mL) for 48 hours. Adherent cells were washed 3× with PBS 
to remove phorbol 12-myristate 13-acetate and subsequently 
allowed to rest in complete RPMI for 24 hours before transfec-
tion. Cells were transfected with either 5 pmol UTY GapmeR 
(product sequence 5′-3′: AATGGAGTGTCTGTGC; Qiagen), neg-
ative control A (product sequence 5′-3′: AACACGTCTATACGC; 
Qiagen), or Block-iT Fluorescent Oligo (Invitrogen) as trans-
fection control, using the Lipofectamine RNAiMAX Reagent 
(Invitrogen) following manufacturer’s instructions. To induce 
macrophage activation, lipopolysaccharide from Escherichia coli 
0111:B4 (100 ng/mL; Sigma) was added to the cultures. Cells 
were incubated at 37°C, 5% CO2 for 48 hours. Five experi-
mental replicates of each control and knockdown transfection 
were performed.
Flow Cytometry
Cells were harvested and washed in PBS. After blocking Fcγ 
receptors (5% mouse serum and 0.001% sodium azide in 
2.4G2 cell culture supernatant) for 10 minutes at 4°C, cells 
were stained for 30 minutes with the following anti-human 
antibodies: CD14 (Pe-Cy7) expressed on macrophages, CD80 
(FITC), CD83 (APC), and HLA-DR (e450) or their respec-
tive isotype controls (all Thermofisher UK). Unbound antibody 
was washed off, and cells have been stained for viability using 
Fixable Viability Dye eFluor 780 (eBioscience). Events have 
been acquired using the LSR2 and Fortessa flow cytometers 
(BD Bioscience) and analyzed using FlowJo (Tree Star) soft-
ware. The differences between 2 contrasting experimental con-
ditions were examined by a Mann-Whitney U test.
The studies adhered to the Declaration of Helsinki and 
were approved/ratified by the NHS National Research Ethics 
Service North West (United Kingdom), the Leicestershire 
Health Authority Ethics Committee (United Kingdom), and the 
Ethics Committee of Karolinska University Hospital (Sweden). 
Informed written consent was obtained from all recruited 
individuals.
RESULTS
The Main Northern European Lineage of 
Haplogroup I (Haplogroup I1) Is Associated 
With Increased Risk of CAD
A total of 162 single-nucleotide variants of the Y chro-
mosome survived the QC filters and were informative in 
the phylogenetic analysis (Figure I in the online-only Data 
Supplement). Of 225 516 men recruited in UK Biobank, 
168 686 individuals of white European ancestry had 
MSY genotype information sufficient for the resolution of 
their Y chromosome haplogroup. Based on this informa-
tion, we identified 85 distinct haplogroups (Figure 1A), 7 
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groupings of which were present in at least 1% of the UK 
population (Figure 1A). A total of 129 133 men classified 
into one of 7 common haplogroups had full phenotypic 
information required for the genetic association analysis 
(Figure II in the online-only Data Supplement; Table II in 
the online-only Data Supplement). Using the diagnostic 
decision algorithm, we classified them into individuals with 
CAD (cases, 11 234) and CAD-free controls (controls, 
117 899; Figure III in the online-only Data Supplement). 
Their clinical characteristics are shown in Table XVII in 
the online-only Data Supplement. Only one of 7 exam-
ined MSY haplogroups was related to CAD after adjust-
ing for its risk factors, genetic principal components, 
and genotyping array (Figure 1B; Tables III through IX 
in the online-only Data Supplement). Indeed, haplogroup 
I1 (most common in Northern Europe) was coupled with 
≈11% excess of CAD risk when compared with other 
MSY lineages (odds ratio, 1.11; 95% CI, 1.04–1.18; 
Figure 1. The Y chromosome and coronary artery disease.  
A, Phylogenetic analysis of the Y chromosome in UK Biobank. Colored (matched to Hallast et al) groups of tree branches examined for 
association with coronary artery disease (CAD) and their respective frequencies. B, Odds ratios for CAD in men with haplogroup I1 compared 
with men with other haplogroups of the Y chromosome. Error bars show the lower and upper bounds of the 95% CI. The size of the point 
reflects the level of statistical significance after correction for multiple testing (associations that survived the correction for multiple testing are 
shown as large points). C, Two hundred thirty-five genetic variants specific to haplogroup I1 uncovered through DNA sequencing of male-
specific region of the Y chromosome (MSY). Variant locations are visualized as radial lines (2) originating in the outermost gray circle in the 
context of known protein-coding genes (red boxes), noncoding genes (yellow), and pseudogenes (blue boxes) of the Y chromosome; gene 
symbols are external to the outermost circle (1). Links to the inner circles are colored in green for variants mapping to genes and gray for 
intergenic variants. The number of datasets in which each variant appears (3) is scaled from light yellow (1) to dark red (3). Single-nucleotide 
substitutions are shown in yellow and insertion-deletions in turquoise (4). Novel variants are also highlighted in turquoise (5). D, Thirty-one 
genetic variants exclusive to haplogroup I1 shown in context of the summarized Roadmap Epigenomics chromatin states from 21 epigenomes 
of relevance to atherosclerosis/CAD. Individual epigenomes are grouped under the same type of cell/tissue. Red denotes a transcription start 
site state; yellow, an enhancer state; green, a transcribed state; and pale gray, a silent state. MSY gene symbols are annotated above the heat 
map variant identifier (wherever present).
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P=6.8×10−4; Figure 1B; Table III in the online-only Data 
Supplement). We validated the association between hap-
logroup I1 and CAD (Table XVIII in the online-only Data 
Supplement) using a different set of diagnostic criteria 
of CAD applied previously to UK Biobank by Klarin et 
al.10 Further studies conducted on all pairwise combina-
tions of the 7 haplogroups confirmed that statistically 
significant associations with CAD were apparent only in 
the analyses of haplogroup I1 (Figure 1B; Table XIX in 
the online-only Data Supplement). They also revealed a 
consistency in the direction of effect of haplogroup I1 on 
the risk of CAD irrespective of which other haplogroup 
was used as a comparator (Table XIX in the online-only 
Data Supplement). No statistically significant differences 
in the risk of CAD were detected between any pair of 
haplogroups other than I1 (Table XIX in the online-only 
Data Supplement).
Collectively, in the largest population of men to date 
with a resolved MSY phylogeny, we identified the associ-
ation between CAD and haplogroup I1 and showed that 
other common Y chromosome lineages do not predis-
pose their carriers to increased CAD risk.
Two Hundred Thirty-Five Genetic Variants 
Track Exclusively With Haplogroup I1 Along 
the Paternal Line—Next-Generation DNA 
Sequencing of MSY
To identify variants that are inherited exclusively from hap-
logroup I1, we compared DNA profiles of 50 haplogroup 
I1 chromosomes against all other Y chromosome lineages 
using data from 3 separate DNA-sequencing experiments 
covering 10.4 Mb (44%) of the euchromatic portion of the 
MSY. This analysis revealed 235 variants unique to carri-
ers of haplogroup I1 (Figure 1C; Table XX in the online-
only Data Supplement). Of those, 228 (97%) were SNPs 
and 7 (3%) were insertion-deletions. The identified hap-
logroup I1–specific variants are dispersed throughout the 
euchromatic MSY with one polymorphic site per 44.2 kb 
of the sequenced region on average. Fifty (21%) variants 
are present within a total of 23 known MSY genes with 
26 (52%) of these variants internal to the 15 single-copy 
“X-degenerate” genes of the Y chromosome. None of 
the identified haplogroup I1–specific variants were within 
translated exons of MSY protein-coding genes (Figure 1C; 
Table XX in the online-only Data Supplement).
Taken together, these experiments showed that 
although a high number of variants are inherited together 
as haplogroup I1, none of them appear to act through 
changes in amino acid sequence of MSY proteins.
Genetic Variants Exclusive to Haplogroup I1 Are 
Enriched for Active Chromatin States in Cells 
and Tissues of Relevance to Atherosclerosis
To further functionally characterize haplogroup I1–spe-
cific variants, we first mapped them onto chromatin reg-
ulatory elements derived from a core set of 5 histone 
modifications in Roadmap Epigenomics.20 Specifically, 
we examined an overlap between each of 235 identi-
fied variants and 4 combinatorial chromatin states (Fig-
ure 1D; Table XIII in the online-only Data Supplement), 
including transcription start site (“Tss”), enhancer (“Enh”), 
transcribed (“Tx”), and “silent/other” across 21 epig-
enomes derived from cells/tissues of relevance to ath-
erosclerosis/CAD. Of 4935 annotations (235 variants 
by 21 epigenomes), 393 (8%) haplogroup I1–specific 
annotations overlapped with at least one active (associ-
ated with expressed genes) state20 in the set of exam-
ined cell/tissues (Figure 1D). Forty, 79, and 274 of these 
annotations were classified as “Tss” (associated with pro-
moter regions), “Enh” (associated with enhancer regions), 
and “Tx” associated with transcribed regions, respectively 
(Figure 1D).
Using the same chromatin segmentation states 
across 21 epigenomes of atherosclerosis-relevant 
cells/tissues, we then determined the enrichment for 
active states between variants specific to haplogroup I1 
versus any other MSY genetic variants (with at least 1% 
frequency in European populations). Given the demon-
strated association between CAD and haplogroup I1, 
we have hypothesized that it may be enriched for vari-
ants that overlap active chromatin states in cell types/
tissues of relevance to atherosclerosis. This analysis 
demonstrated that haplogroup I1–specific variants 
show 2.45- and 1.56-fold enrichment for active chro-
matin states associated with promoters and enhanc-
ers in cells/tissues of relevance to atherosclerosis 
when compared with nonhaplogroup I1 MSY variants 
(P=1×10−6 and P=1.15×10−4), respectively. To exclude 
a potential detection bias (driven by targeted sequenc-
ing of potentially functional regions of MSY in hap-
logroup I1 carriers), we conducted further sensitivity 
analyses using 1000 Genomes Project data as an 
exclusive source of information on MSY variants for all 
haplogroups. These sensitivity analyses confirmed the 
enrichment for Tss and enhancer categories for hap-
logroup I1 when compared with other MSY variants 
(P=1.0×10−4 and P=1.39×10−2), respectively. Finally, 
we examined whether haplogroup I1 variants are 
enriched for active chromatin states only in CAD-rele-
vant epigenomes or whether this is also seen in other 
epigenomes not related to atherosclerosis/CAD. We 
used a million permutations of our chromatin state data 
from epigenomes that were not included in the athero-
sclerosis/CAD-relevant set and found no evidence of 
enrichment for promoters (0.85-fold; P=0.9880) but a 
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statistically significant enrichment for enhancers (1.70-
fold; P=5×10−6) when comparing I1-specific variants 
with common MSY variants. We have also determined, 
by a further 1 million permutations, that the enrichment 
for promoter states is specific to atherosclerosis epig-
enomes when compared with nonatherosclerosis epig-
enomes (P=2×10−6) but that this is not the case for the 
enhancer state (P=0.6530).
To provide global genomic context to the magnitude 
of haplogroup I1–specific enrichment for active chroma-
tin states, we compared all known expression quantita-
tive loci (eSNPs) identified by GTEx in 2 relevant tissues 
against non-eSNP autosomal variants (with minor allele 
frequency >1%) using the same active chromatin states 
in 2 overlapping Roadmap Epigenomics tissues. eSNPs 
show a similar (to variants of haplogroup I1) magnitude 
of enrichment for active chromatin states (“Tss”: 3.02-
fold enrichment, P=3.1×10−5; “Enh”: 1.25-fold enrich-
ment, P=2.3×10−5).
Taken together, these results show that the Y chromo-
some sequence of haplogroup I1 is enriched for variants 
overlapping with the 2 most active chromatin states that 
regulate gene expression in human cells and tissues and 
that the magnitude of this enrichment is similar to that 
of eSNPs.
Haplogroup I1 Is Associated With Changes 
in Numerous Pathways of Relevance to 
Atherosclerosis in Men From the General 
Population
Using MSY genotypes, we divided GTEx men into car-
riers of haplogroup I1 and other lineages, respectively 
(Table XIV in the online-only Data Supplement). There 
were no statistically significant differences in 3 genetic 
principal components between the groups (Table XXI in 
the online-only Data Supplement). We then examined 
differences in gene expression sets between these 2 
groups using RNA sequencing–derived transcriptome 
profiles for 8 tissues of relevance to atherosclerosis/
CAD (online-only Data Supplement). A total of 104 gene 
sets showed significant association with haplogroup 
I1 in at least one of 8 GTEx tissues (Figure IV in the 
online-only Data Supplement; Table XXII in the online-
only Data Supplement). Based on prior knowledge of 
function of differentially expressed leading edge genes, 
we clustered the haplogroup I1–associated gene sets 
into 13 overarching biological themes bringing together 
individual pathways implicated in GSEA under common 
biological processes. A total of 28 individual pathways 
were related to immunity; this was identified as the domi-
nant theme underpinning the signature of haplogroup 
I1 in tissues of relevance to atherosclerosis/CAD. The 
pattern of immune gene expression implicated through 
GSEA was consistent with the inhibition of MHC class I 
and II–restricted antigen presentation, antigen process-
ing, reduced costimulation, and upregulation of the com-
plement system in men with haplogroup I1 (Figure 2A; 
Table XXII in the online-only Data Supplement). Our 
GSEA also revealed the association between haplogroup 
I1 and several pathways of viral infection accompanied 
by reduction in expression of genes underpinning the 
host response to viruses (Figure 2A; Table XXII in the 
online-only Data Supplement). Compared with men from 
other MSY lineages, carriers of haplogroup I1 showed 
alterations in gene expression in pathways responsible 
for fundamental defence mechanisms against patho-
gens including phagocytosis and lysosomal processing. 
Haplogroup I1 individuals also showed gene expression 
changes in pathways underpinning oxidative phosphory-
lation, mitochondrial respiration, and extracellular matrix 
remodeling (Figure 2A; Table XXII in the online-only 
Data Supplement).
In summary, this suggests that men with haplogroup 
I1 exhibit alterations in different molecular cascades 
known for their role in both early and late stages of ath-
erosclerosis and that these gene expression changes 
are apparent in several types of cells and tissues of rel-
evance to CAD.
Haplogroup I1 Is Associated With Changes 
in Numerous Pathways of Relevance to 
Atherosclerosis in Men With CAD
We then examined the effect of haplogroup I1 on gene 
expression programmes in 4 relevant tissues from Swed-
ish men affected by CAD in STAGE.25 We assigned all 
men with informative MSY phylogeny into either hap-
logroup I1 or other lineages and conducted a compara-
tive transcriptome-wide analysis between these groups 
(Table XV in the online-only Data Supplement). There 
were no statistically significant differences in 3 genetic 
principal components between the groups (Table XXIII 
in the online-only Data Supplement). Our GSEA-based 
analysis revealed 279 pathways showing differential 
expression between men with haplogroup I1 and those 
from other lineages in at least one of 4 examined tis-
sues (Table XXIV in the online-only Data Supplement; 
Figure V in the online-only Data Supplement). The hap-
logroup I1–associated pathways mapped onto 13 over-
arching biological themes, 10 of which overlapped with 
the themes identified in the GTEx analysis. A total of 36 
pathways showed directionally consistent associations 
with haplogroup I1 between STAGE and GTEx analysis 
(Table XXV in the online-only Data Supplement). Many 
of these replicated I1-associated pathways (including 
those involved in energy production and metabolism, 
extracellular matrix remodeling, immunity, and response 
to infections) have strong relevance to atherosclerosis 
(Table XXV in the online-only Data Supplement). A num-
ber of additional pathways associated with haplogroup 
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I1 in STAGE, while different in name to the ones iden-
tified in GTEx, overlapped biologically with themes and 
subthemes of haplogroup I1 signature identified in GTEx 
(Figure 2B).
We have further identified 22 pathways, exclusive to 
our STAGE analysis with a clear prior connection to ath-
erosclerosis. Those mapped onto 3 overarching themes, 
including immune system, lipids, and coagulation and 
hemostasis (Figure 2B). The gene expression patterns 
within some of those pathways suggested upregula-
tion of proatherogenic lipoprotein transport metabo-
lism within the arterial wall, increased transendothelial 
migration of blood leukocytes, activated blood platelets, 
and prothrombotic phenotype within the arterial wall of 
Figure 2. Biological pathways of gene expression modified in men from haplogroup I1 when compared with other haplogroups.  
 Genotype-Tissue Expression (GTEx) project (A) and STAGE (Stockholm Atherosclerosis Gene Expression; B) results are shown separately. 
Tissues where a given pathway is associated with haplogroup I1 are shown as colored points; yellow, heart; brown, adipose tissue; and 
turquoise, arterial tissue. Pathways are numbered as per Tables XXII (GTEx) and XXIV in the online-only Data Supplement (STAGE). Colored 
links associate pathways with specific biological themes; color is determined by the functional theme, and each theme is labeled.
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men with haplogroup I1 when compared with other lin-
eages (Table XXIV in the online-only Data Supplement; 
Figure 2B).
The results of secondary sensitivity analyses (con-
ducted in STAGE to account for additional clinical 
cofounders) were largely consistent with the data from 
the primary analysis (Table XVI in the online-only Data 
Supplement).
In summary, we have replicated several associations 
between haplogroup I1 and changes in gene expres-
sion pathways underpinning fundamental mechanisms 
of atherosclerosis including defence against infections, 
innate and adaptive immunity, mitochondrial respiration, 
and processes of extracellular matrix remodeling. In addi-
tion, we revealed that in the presence of CAD, men with 
haplogroup I1 show upregulation in expression of genes 
from lipid, coagulation, and additional immune pathways, 
consistent with their increased susceptibility to athero-
sclerosis when compared with carriers of other Y chro-
mosome lineages.
Reduced Expression of Macrophage UTY Leads 
to Gene Expression Changes Partly Consistent 
With Those Associated With Haplogroup I1
Given the key role of macrophages in atherosclerosis 
and the previously demonstrated effect of haplogroup I 
on the transcriptome of blood-derived macrophages,5,30 
we chose this cell type as a model for in vitro experi-
ments. We selected UTY as the MSY target for these 
studies given that it was the only one of 11 ubiquitously 
expressed MSY protein-coding genes associated with 
haplogroup I1 in blood from the STAGE study (Figure 3A; 
Figure VI in the online-only Data Supplement).
We then used synthetically stabilized complementary 
RNAs to target and experimentally reduce UTY mRNA 
expression in macrophages. We confirmed the efficacy of 
the experiment by both RNA sequencing and quantitative 
polymerase chain reaction; they showed 1.44- and 1.6-
fold downregulation of UTY mRNA expression, respec-
tively (Figure 3B). This drop in macrophage expression 
is similar to the effect of haplogroup I1 on blood UTY 
in STAGE (Figure 3A) and that of haplogroup I on mac-
rophage UTY expression in our previous gene expres-
sion analysis.30 We also confirmed that the expression of 
the X-chromosome paralog (UTX) did not change in this 
experiment (P=0.5634; Figure VII in the online-only Data 
Supplement).
The experimental reduction of UTY expression resulted 
in changes of macrophage expression of 59 pathways 
(Table XXVI in the online-only Data Supplement); 6, 17, 
and 5 of the identified pathways overlapped directly with 
those associated with haplogroup I1 in tissues from 
GTEx, STAGE, or both, respectively (Figure 3C; Tables 
XXVII through XXX in the online-only Data Supplement). 
With 13 overlapping pathways mapping onto immunity 
(primarily: inhibition of MHC class I and II–restricted anti-
gen presentation, as well as antigen processing), immune 
system was the most prominent theme intersecting the 
effects of haplogroup I1 and UTY knockdown on the 
transcriptome (Figure 3D; Tables XXVII through XXIX in 
the online-only Data Supplement). Among overlapping 
gene expression signals, we also observed pathways of 
response to viral infections and upregulation in genes 
within the coagulation and hemostasis pathway known 
for its role in atherosclerosis (Figure 3D; Tables XXVII 
through XXIX in the online-only Data Supplement).
To further examine the effect of UTY on adaptive 
immune responses in vitro, we experimentally reduced 
UTY expression in phorbol 12-myristate 13-acetate–
treated and lipopolysaccharide-stimulated THP-1 cells 
and measured the expression of key molecules involved 
in antigen presentation and costimulation (MHC class 
II cell surface receptor—HLA-DR, CD80, and CD83) 
in these cells. We found that experimental reduction of 
UTY leads to a decrease in median fluorescent intensity 
for CD80 and CD83, as well as HLA-DR in these cells 
(Figure 3E).
Collectively, these data demonstrate a significant 
overlap in biological processes underpinning the gene 
expression profile between the experimental reduction 
of UTY in macrophages and haplogroup I1 association 
in tissues of relevance to atherosclerosis. This suggests 
that UTY can at least partly mediate the effect of hap-
logroup I1 on gene expression programmes and that 
some of them may be related to suppression of immunity 
and increased susceptibility to atherosclerosis.
DISCUSSION
Our study provides several novel insights into the rela-
tionship between the Y chromosome and predisposi-
tion to atherosclerosis in men. First, we identified that 
haplogroup I1 is the only common UK lineage of the Y 
chromosome associated with CAD in white British men. 
Second, we showed that numerous sequence variants 
inherited from father to son exclusively with this Y chro-
mosome lineage are enriched in active chromatin regions 
within cells/tissues of relevance to atherosclerosis and 
as such may mediate the effect of haplogroup I1 on 
CAD. Third, our transcriptome-wide analyses in several 
human tissues revealed that the genetic effects of hap-
logroup I1 translate into modified gene expression pro-
grammes of direct relevance not only to atherosclerosis 
and the cardiovascular system but more generally to vital 
molecular and physiological processes. Among these, the 
suppression of immunity and defence against infections, 
changes in mitochondrial respiration, proatherogenic and 
prothrombotic phenotype, and alterations in extracellular 
matrix remodeling were the most consistent signatures 
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of haplogroup I1 on the transcriptome. Finally, we identi-
fied one MSY gene (UTY) as a likely mediator of at least 
some of the haplogroup I1–associated effects on the 
human transcriptome.
The origins of haplogroup I date back to the Palaeoli-
thic period, earlier than 20 000 years ago12; however, its 
2 sublineages subsequently followed different histories. 
While haplogroup I2 (most common in south-eastern 
Europe) is diverse and ancient with a Palaeolithic age 
of ≈18 000 years, the CAD-associated haplogroup I1 is 
one of a number of European expansion lineages31 that 
have spread relatively recently. Its most recent common 
ancestor lived in the Bronze Age, only about 4000 years 
ago.11 Haplogroup I1 has a Northern European distribu-
tion,32 with the highest frequency in Scandinavia (≤37% 
in Sweden), and a declining frequency gradient south-
ward. Popular interpretations suggest that the spread 
of this lineage was by migrating Vikings (https://www.
eupedia.com/europe/Haplogroup_I1_Y-DNA.shtml), 
although no evidence has been presented for this in the 
Figure 3. UTY, haplogroup I1, gene 
expression and immunity.  
A, Difference in blood UTY expression 
between haplogroup I1 and other Y 
chromosome lineages in STAGE (Stockholm 
Atherosclerosis Gene Expression); P, level 
of statistical significance. B, Difference in 
UTY gene expression quantified by RNA 
sequencing between human macrophages 
incubated with an antisense RNA specific 
to UTY (knockdown) and macrophages 
incubated with a scrambled antisense RNA 
(control); P, level of statistical significance. 
C, Venn diagram showing numbers of 
replicating pathway results between each of 
the 3 analyses. D, Circular representation of 
all significant pathways overlapping between 
the analyses (Genotype-Tissue Expression 
[GTEx] project, STAGE, or UTY knockdown). 
Proceeding from the periphery inwards, 
numbers are unique identifiers linked to each 
pathway (Table XXX in the online-only Data 
Supplement). Colored regions represent 
distinct pathway themes, proceeding from 
vertical in a clockwise direction, these are 
cell contact (in green), cell cycle, cellular 
transport, coagulation and hemostasis, 
energy production and metabolism, 
extracellular matrix, immune system, other, 
transcription, translation, and viral infection 
(dark red). Colored tiles represent each 
pathway in one of 3 analyses; each analysis 
is labeled. The color of each tile denotes 
the direction of association between the 
expression of a pathway and haplogroup 
I1/UTY knockdown (blue, negative; red, 
positive). The color intensity of a tile denotes 
the significance of the association. E, 
Median fluorescent intensity for CD80, 
CD83, and HLA-DR in lipopolysaccharide-
stimulated THP-1 cells after treatment with 
UTY-specific knockdown antisense RNA 
GapmeRs and scrambled control; P, level of 
statistical significance.
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scientific literature to date. Interestingly, this geographic 
gradient in haplogroup I1 distribution in Europe corre-
lates with a well-known north-south difference in preva-
lence of CAD.33
Since its divergence from a common ancestor with 
haplogroup I2, haplogroup I1 has accumulated a large 
number of single genetic variants before its recent 
expansion. We provide comprehensive functional anno-
tations of these variants in cells/tissues of relevance 
to atherosclerosis and demonstrate the enrichment of 
haplogroup I1–exclusive noncoding variants for tran-
scription start sites and enhancers. Genetic variants 
having such characteristics are also overrepresented 
among autosomal signals from genome-wide associa-
tion studies.34,35 This suggests that regulatory variants 
tracking with haplogroup I1 may be important for male 
health and disease. We did not examine whether other 
haplogroups of the Y chromosome individually show 
enrichment for active chromatin states in cells and tis-
sues of relevance to atherosclerosis given that none of 
them showed individual associations with CAD. While all 
I1-specific variants are inherited together from father to 
son within a single block of DNA, their individual effects 
on specific cells and tissues differ; for example, some of 
them show operational activity only in selected tissues, 
whereas others appear to act in a more ubiquitous man-
ner. We anticipate that the cumulative regulatory effect 
of variants in active chromatin regions is most likely to 
mediate the ultimate effect of haplogroup I1 on the male 
transcriptome, which shapes phenotypic differences 
between men. Because of the lack of crossing-over 
within the MSY, fine mapping cannot be used to dissect 
their individual contributions, and experimental strate-
gies such as CRISPR/Cas9 gene editing will instead be 
necessary to define their individual effects.
Our transcriptomic analyses provided compelling evi-
dence for the global effects of haplogroup I1 on basic 
molecular/cellular pathways including those involved in 
transcription, translation, cell cycle, and metabolism. This 
is consistent with the increasingly recognized role of 
ubiquitously expressed MSY genes on RNA and protein 
metabolism in human tissues.3 However, the most appar-
ent themes of haplogroup I1–associated pathways were 
those of direct relevance to atherosclerosis, in particular, 
the modified expression of genes in pathways respon-
sible for antigen presentation and processing, as well as 
response to infections. Associations between Y chro-
mosome and influenza A and coxsackievirus B3 infec-
tions were noted before in rodent models.36,37 Chronic 
infections including those by HIV-1 and influenza A are 
also increasingly recognized as a nontraditional risk fac-
tor of atherosclerosis through deregulation of immune 
and inflammatory response.38,39 The observed suppres-
sion of gene expression programmes within pathways 
underpinning the host response to viral infections in men 
with haplogroup I1 may potentially translate (through 
impaired defence mechanisms) into increased suscep-
tibility, faster progression, and worse health outcomes 
in carriers of this haplogroup when compared with the 
other MSY chromosome lineages. Indeed, men with hap-
logroup I (of which haplogroup I1 forms a part) showed 
faster progression of HIV-1 infection to AIDS, higher 
rates of AIDS-related mortality, and worse response to 
retroviral therapy than men with other MSY lineages.40 
Whether the paternally inherited suppressed response to 
viral infections associated with haplogroup I1 extends to 
other infections (which are not represented in our path-
way repositories) remains unclear.
We also observed changes in gene expression within 
other pathways underlying almost all stages of CAD 
including the initiation, growth, and rupture of athero-
sclerotic plaque (ie, leukocyte transendothelial migration, 
genes involved in lipoprotein metabolism, genes encod-
ing enzymes, and their regulators involved in the remodel-
ing of the extracellular matrix).41,42 Indeed, a key leading 
edge gene in the majority of lipid pathways upregulated 
in arteries from carriers of haplogroup I1 was the apoli-
poprotein B gene—a marker of cholesterol-rich lipopro-
teins—known as the critical driver of atherosclerosis.43 
In addition, CAD patients with haplogroup I1 showed 
upregulation of pathways involved in platelet aggregation 
and arterial thrombus formation (genes involved in ADP 
signaling through P2Y purinoceptor 12, genes involved in 
formation of fibrin clot [clotting cascade])44—precipitants 
of myocardial infarction.45 The gene products in these 
pathways are well-established targets in pharmacologi-
cal management of atherosclerosis.46 The assessment of 
the extent to which the uncovered associations between 
haplogroup I1 and gene expression pathways are specific 
to one type of cell/tissue requires further studies. How-
ever, it is becoming increasingly clear that many of the 
disease-relevant genetic variants do not necessarily act 
in a tissue-specific manner, that is, in our recent analysis 
of variants associated with chronic kidney disease, <20% 
show truly kidney-specific effects on gene expression.47
Our data suggest that UTY may mediate at least some 
of the effects of the Y chromosome on the human tran-
scriptome. As a minor histocompatibility antigen, UTY is 
a well-known contributor to the regulation of immune 
response.48 It also emerges that UTY may be involved 
in host response to viral infections through contribu-
tions to antigen processing and presentation.49 To this 
end, the dominance of immunity in the overlap between 
haplogroup I1–associated and UTY-related pathways is 
perhaps not surprising. To what extent the role of UTY 
in human immunity is driven by its function as a histone 
H3K27me3 demethylase remains to be established.50 
Abundant in immune cells, H3K27me3 is considered as 
repressive to gene expression, and H3K27 demethylases 
promote transcription by removing the repressive histone 
mark.51 UTY shows somewhat reduced demethylase 
activity compared with its X-chromosome gametolog50 
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(UTX), but it also exhibits additional demethylase-inde-
pendent chromatin remodeling activities.52,53 These data 
suggest that UTY can influence gene expression pro-
grammes and immunity-related processes, and its down-
regulation within cells of relevance to atherosclerosis 
may contribute to the development of at least some of 
the observed haplogroup I1–related molecular and clini-
cal manifestations.
In summary, in the largest genetic association analy-
sis to date, of 129 133 Y chromosomes, we show that a 
common Northern European lineage (haplogroup I1) of 
the MSY is enriched for multiple transcriptionally active 
variants and increases cardiovascular risk through pro-
atherosclerotic reprogramming of the transcriptome in 
several tissues of key relevance to CAD. Our data also 
suggest that at least some of these changes may be 
mediated by downregulation of UTY. These data illumi-
nate the powerful pleiotropism of the MSY on men’s car-
diovascular health and disease.
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